A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity

Inclusion Criteria: * Adult patients diagnosed with focal ULS and/or LLS for whom aboBoNT-A (Dysport®) was prescribed in line with the SmPC (according to clinician judgement). * Patients initiated on aboBoNT-A for focal ULS after the 31st January 2016 and/or for focal LLS after the 06th December 2016. * Patients receiving ≥1 injection(s) (i.e. ≥1 treatment cycle) of aboBoNT-A during the observation period, in line with Dysport® Summary of Product Characteristics (SmPC). * Patients aged ≥18 years old at the time of the first aboBoNT-A injection for focal ULS and/or LLS. * Patient is naïve to treatment with any type of BoNT-A during the 6 months prior to initiation of aboBoNT-A. * Patients treated at the participating centre for the duration of the observation period, with data recorded in the medical records available for review. Exclusion Criteria: * Patients with an interval of \<12 weeks between aboBoNT-A treatments * Patients are participating (or who have participated) in an interventional clinical trial of an investigational medicinal product indicated for spasticity which may influence and confound the real-world data collected for this study. * Patients treated with aboBoNT-A off-license, this may include off-license indications, muscles indicated for injection or dosing